1259614-21-5

Basic information

• Product Name: methyl 3-(4-(2-acetylhydrazinecarbonyl)phenoxy)-5-(benzyloxy)benzoate
• Synonyms: methyl 3-(4-(2-acetylhydrazinecarbonyl)phenoxy)-5-(benzyloxy)benzoate
• CAS NO: 1259614-21-5
• Molecular Weight: 434.448
• Mol File: 1259614-21-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 3-(4-(2-acetylhydrazinecarbonyl)phenoxy)-5-(benzyloxy)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-(4-(2-acetylhydrazinecarbonyl)phenoxy)-5-(benzyloxy)benzoate(1259614-21-5)
• EPA Substance Registry System: methyl 3-(4-(2-acetylhydrazinecarbonyl)phenoxy)-5-(benzyloxy)benzoate(1259614-21-5)

Safety Data

• Hazardous Substances Data: 1259614-21-5(Hazardous Substances Data)

Upstream product

• 1259614-22-6 4-[3-(benzyloxy)-5-(methoxycarbonyl)phenoxy]benzoic acid 
• 1259614-23-7 methyl 3-(benzyloxy)-5-(4-formylphenoxy)benzoate 
• 459-57-4 4-fluorobenzaldehyde 
• 54915-31-0 methyl 3-(benzyloxy)-5-hydroxybenzoate 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 
• 1068-57-1 acetic acid hydrazide 
• 100-39-0 benzyl bromide 

Downstream Products

• 1259614-20-4 methyl 3-(benzyloxy)-5-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy)benzoate 
• 1259614-19-1 methyl 3-hydroxy-5-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy)benzoate 
• 1263403-98-0 S-(-)-3-[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy]-5-[(1-methyl-2-oxo-pyrrolidin-3-yl)oxy]benzoic acid 
• 1263402-76-1 (S)-3-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy)-5-((1-methyl-2-oxopyrrolidin-3-yl)oxy)-N-(thiazol-2-yl)benzamide 
• 1263403-99-1 (S)-(-)-methyl 3-[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy]-5-[(1-methyl-2-oxo-pyrrolidin-3-yl)oxy]benzoate 
• 1263404-00-7 (S)-(-)-methyl 3-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy)-5-((2-oxopyrrolidin-3-yl)oxy)benzoate 
• 1263402-84-1 (R)-3-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy)-5-((1-methyl-2-oxopyrrolidin-3-yl)oxy)-N-(thiazol-2-yl)benzamide 
• 1263404-01-8 (R)-(+)-3-[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy]-5-[(1-methyl-2-oxo-pyrrolidin-3-yl)oxy]benzoic acid 
• 1263404-02-9 (R)-(+)-methyl 3-[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy]-5-[(1-methyl-2-oxo-pyrrolidin-3-yl)oxy]benzoate 
• 1263404-03-0 (R)-(+)-methyl 3-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy)-5-((2-oxopyrrolidin-3-yl)oxy)benzoate 
• 1263403-94-6 3-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy)-5-(1-methyl-2-oxo pyrrolidin-3-yloxy)benzoic acid 
• 1263402-17-0 N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-3-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy)-5-((1-methyl-2-oxopyrrolidin-3-yl)oxy)benzamide 
• 1263402-22-7 3-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy)-5-(1-methyl-2-oxopyrrolidin-3-yloxy)-N-(4-methylthiazol-2-yl)benzamide 
• 1263402-10-3 3-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy)-5-(1-methyl-2-oxopyrrolidin-3-yloxy)-N-(thiazol-2-yl)benzamide 

Relevant articles and documents

SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS

The present invention relates to substituted benzamide derivatives of the general Formula I and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, prodrugs, metabolites, and polymorphs and can be use

DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS

The invention relates to disubstituted benzamide derivatives of the general Formula (I), their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, prodrugs, metabolites and polymorphs. The invention also re